CLINICAL AND BIOCHEMICAL EFFECTS OF LIFESTYLE MODIFICATION WITH PENTOXIFYLLINE, VITAMIN E IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS IN SULAIMANI

Authors

  • Chra Salahalddin Ahmed Department of Clinical Pharmacy, College of Pharmacy, University of Sulaimani, Kurdistan Region, Iraq.
  • Haydar Al-Tukmagi Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Iraq.
  • Mohammed Omer Mohammed Department of Medicine, College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.

DOI:

https://doi.org/10.17656/jsmc.10214

Keywords:

NASH, Lifestyle, Pentoxifylline, Vitamin E, KCGH, Tricuspid atresia, Echocardiography, Single ventricle, Sulaimani

Abstract

Background 

The burden of Non-Alcoholic Steatohepatitis is growing and current pharmacologic treatments are limited by adverse effects and inconsistent efficacy. Pilot studies suggest that Pentoxifylline and vitamin E can reduce degree and pattern of fatty liver, liver enzyme and inflammatory marker in patients with NASH. 

Objectives 

Evaluation of the clinical, biochemical and ultrasonographic effects of pentoxifylline, and vitamin E in patients with non-alcoholic steatohepatitis.

Methods

A total of 110 participants with NASH which diagnosed by ultrasonography fatty infiltration and raised aminotransferase level were included, only 90 participants completed the study. Demographic data, anthropometric measures such as Body Mass Index (BMI), waist/hip ratio were taken, liver function test, lipid profile, blood glucose, serum creatinine and High sensitivity C-reactive protein (Hs-CRP). The patients were divided into three comparable groups in age, gender and BMI. All enrolled participants were treated by lifestyle modification but pharmacologically they were randomly divided into three groups and followed for 6 months. Group 1; treated with placebo as a control group (starch prepared by capsule 400mg twice daily). Group 2; treated with vitamin E soft gelatin capsule 400 IU twice daily.Group 3; treated with pentoxifylline caplet 400mg twice daily.

Results

Out of 110 participants, only 90 participants (48 male, 42 female) completed this study, with age range of 23-65 years with age mean was 42.1±11.2. All the three groups showed decreased steatosis by ultrasonography and a significant reduction in aminotransferase levels, Hs-CRP, lipid profile, blood glucose, blood pressure and waist circumference compared to baseline. In the pentoxifylline group, side effects such as nausea, heartburn and dizziness were noted while in vitamin E group; abdominal pain and blurred vision were recorded after the second visit. 

Conclusions

Pentoxifylline or Vitamin E with dietary changes and exercise led to significant improvement in hepatic steatosis indicated by ultrasonography, reduction in aminotransferase levels and improved inflammatory marker (Hs-CRP).

References

Naga, C., Z. Younossi, E. Joel, M. Mae, M. Elizabeth. “The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases. American College of Gastroenterology and the American Gastroenterological Association” Am J Gastroenterol 2012; 107 (1): 2005-2023.

Niederau C., Hepatology, NAFLD and NASH, Mauss-Berg, Flying Publisher 2014.

Paredes, A., D. Torres, A. Harrison, ”Nonalcoholic fatty liver disease”, Clin Liver Dis 2012; 16 (1): 397-419, DOI: https://doi.org/10.1016/j.cld.2012.03.005

Roger, K., B. Schindhelm, D. Mechaela, J. Arthur, L. Stanyl, “Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Risk”, Current Diabetes Reports 2007;7 (3): 181-187. DOI: https://doi.org/10.1007/s11892-007-0030-6

Lisa, B., W. Van, M. Elizabeth, W. Sean, M. Richard, “Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial”. Annals of Hepatology 2011; 10 (1): 277-286. DOI: https://doi.org/10.1016/S1665-2681(19)31539-X

Hosseinpanah, F., M. Rambod, L. Sadeghi, L. Hossain, “Predictors of Non-Alcoholic Fatty Liver Disease”. Int J Endocrinol Meta 2007;b 2 (1): 61-69.

Akber, H., and H. Kawther,. “Non-alcoholic fatty liver disease in non diabetic subjects attending a medical outpatient clinic”. Journal of Clinical and Diagnostic Research. (2012);6 (1): 3351-65

Yilmaz, Y., “Review Article: non-alcoholic fatty liver disease and osteoporosis clinical and molecular crosstalk”. Ailment Pharmacol Ther 2012; 36 (1): 45-52. DOI: https://doi.org/10.1111/j.1365-2036.2012.05196.x

Frith, J., P. Day, E. Henderson, L. Newton, A. Burt, ”Non-alcoholic fatty liver disease in older people”. Gerontology 2009; 55 (1): 12-6. DOI: https://doi.org/10.1159/000235677

Rocha, R., H. Cotrim, H. Brega,.“Body mass index and waist circumference in nonalcoholic fatty liver disease”. J Hum Nutr Dietet 2005;.18 (1): 365-70. DOI: https://doi.org/10.1111/j.1365-277X.2005.00634.x

Juan, D., M. Yan-Yan, Y. Chao-Hui, L. You-Ming, “Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis”. World J Gastroenterol 2014; 20 (2): 569-577. DOI: https://doi.org/10.3748/wjg.v20.i2.569

Hoofnagle, J., N. Van, D. Kleiner, M.Clark, V. Kowdley, et al, ”Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis”. Aliment Pharmacol Ther 2013; 38 (1): 134-143. DOI: https://doi.org/10.1111/apt.12352

Younossi, M., J. Reyes, A. Mishra, “Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets”. Aliment Pharmacol Ther 2014;.39 (1): 3-14. DOI: https://doi.org/10.1111/apt.12543

Yin-Mei, L., S. Dede, W. Chun-Tao. ”A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH)”. Hepatology International 2008; 2 (2): 277-286. DOI: https://doi.org/10.1007/s12072-008-9058-1

Zein, O., and R. Lopez. “Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism”, Hepatology 2012; 56 (1): 1291-9.

Kugelmas, A., P. Brian, M. Zobair, J. Tonascia, L. Hazen, “Treatment regimens for non-alcoholic fatty liver disease”. Annals of Hepatology 2009; 8 (1): 3945-54. DOI: https://doi.org/10.1016/S1665-2681(19)31827-7

Claudia, O., L. Rocio, F. Xiaoming, P. John, M. Yerian , “Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism”. Hepatology 2012; 56 (4): 1291-1299. DOI: https://doi.org/10.1002/hep.25778

Bhala, N., P. Angulo P, D. van der Poorten,”The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis. An International Collaborative Study”. Hepatology 2011; 54 (1): 1208-16. DOI: https://doi.org/10.1002/hep.24491

Elzafir, E., H. Linda, M. Zobair, “Expert Review of Endocrinology and Metabolism Current Management of Patients with Nonalcoholic Fatty Liver Disease”. Expert Rev Endocrinol Metab 2013;8 (6): 549-558. DOI: https://doi.org/10.1586/17446651.2013.846212

Wenjun, L., and S. Chunjun,. “Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease”. Lipids in Health and Disease 2011; 49 (1): 2365-2368.

Published

2019-09-21

How to Cite

1.
Ahmed C, Al-Tukmagi H, Mohammed M. CLINICAL AND BIOCHEMICAL EFFECTS OF LIFESTYLE MODIFICATION WITH PENTOXIFYLLINE, VITAMIN E IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS IN SULAIMANI. JSMC [Internet]. 2019 Sep. 21 [cited 2024 Jun. 14];9(3):265-72. Available from: https://jsmc.univsul.edu.iq/index.php/jsmc/article/view/jsmc-10214

Similar Articles

1-10 of 405

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 > >>